Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Dharmalingam M, Aravind SR, Thacker H, Paramesh S, Mohan B, Chawla M, Asirvatham A, Goyal R, Shembalkar J, Balamurugan R, Kadam P, Alva H, Kodgule R, Tandon M, Vaidyanathan S, Pendse A, Gaikwad R, Katare S, Suryawanshi S, Barkate H. Dharmalingam M, et al. Among authors: shembalkar j. Drugs. 2020 Apr;80(6):587-600. doi: 10.1007/s40265-020-01285-0. Drugs. 2020. PMID: 32162274 Free PMC article. Clinical Trial.
Clinical and Demographic Profile of Diabetic Patients from Central India - Results from Diabetes Registry.
Pitale S, Sahasrabuddhe A, Gandhi P, Joshi P, Sakhare A, Balankhe N, Khobragade S, Sengupta S, Ambulkar S, Ganeriwal M, Shembalkar J, Naidu S. Pitale S, et al. Among authors: shembalkar j. Indian J Endocrinol Metab. 2022 Sep-Oct;26(5):471-477. doi: 10.4103/ijem.ijem_63_22. Epub 2022 Nov 22. Indian J Endocrinol Metab. 2022. PMID: 36618524 Free PMC article.
Eruptive xanthomas.
Saoji V, Madke B, Shembalkar J, Rambhia K. Saoji V, et al. Among authors: shembalkar j. BMJ Case Rep. 2024 Apr 16;17(4):e260230. doi: 10.1136/bcr-2024-260230. BMJ Case Rep. 2024. PMID: 38627045 No abstract available.
Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
Sahay RK, Giri R, Shembalkar JV, Gupta SK, Mohan B, Kurmi P, Kumar SR, Sawardekar VM, Mishra A, Murthy LS, Arya VV, Sonawane AR, Soni PN, Gofne SK, Karnawat SR, Rajurkar MN, Patel PM, Lakhwani LK, Mehta SC, Joglekar SJ. Sahay RK, et al. Among authors: shembalkar jv. Adv Ther. 2023 Jul;40(7):3227-3246. doi: 10.1007/s12325-023-02523-z. Epub 2023 May 31. Adv Ther. 2023. PMID: 37258803 Clinical Trial.
Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study.
Ajmani AK, Agrawal A, Prasad BLN, Basu I, Shembalkar J, Manikanth N, Subrahmanyam KAV, Srinivasa M, Chawla M, Srivastava MK, Jebasingh F, Achappa B, Agrawal RP, Pulichikkat RK, Meena R, Bhatia S, Gupta SK, Dange A, Srivastava A, Trailokya A, Shahavi V, Shende S. Ajmani AK, et al. Among authors: shembalkar j. Diabetes Res Clin Pract. 2019 Nov;157:107860. doi: 10.1016/j.diabres.2019.107860. Epub 2019 Sep 14. Diabetes Res Clin Pract. 2019. PMID: 31526825 Clinical Trial.